Investor Presentaiton

Quizartinib QUANTUM-First study data EHA 2022 Highlights (Presidential Symposium) Daiichi-Sankyo Quizartinib + SOC doubled OS in patients with AML 1L with FLT3-ITD mutation vs SOC, regulatory submission planned in FY2022 H1 in JP/US/EU Overall survival probability 1.0 0.8 0.6 Placeboc Primary Endpoint: OS 0.4 MOS: 15.1 mo AMOS: 16.8 mo 0.2 L HR, 0.776 (95% CI, 0.615-0.979) P=.0324 (2-sided) a Quizartinibb MOS: 31.9 mo …………-------- 0.0 T T T 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 57 60 Time, months QUANTUM-First study Ph3 study for patients with newly diagnosed AML with FLT3-ITD mutation ■Efficacy and safety were evaluated in quizartinib + standard chemotherapy arm and placebo + standard chemotherapy arm ■Quizartinib demonstrated a 22.4% reduction in the risk of death compared to standard chemotherapy alone ■Median OS of 31.9m compared to 15.1m with chemotherapy ■No new safety signals were observed a P value was calculated using a stratified log-rank test. b Median follow-up time for quizartinib arm, 39.2 months. c Median follow-up time for placebo arm, 39.2 months. AML: acute myeloid leukemia, OS: overall survival, SOC: standard of care 32

View entire presentation